3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD

Celeste Porsbjerg, Anke H Maitland-van der Zee, Guy Brusselle, Giorgio Walter Canonica, Alvar Agusti, Rosa Faner, Claus F Vogelmeier, Martijn Nawijn, Maarten van den Berge, Franca Rusconi, Charles Pilette, Valeria Ramiconi, Courtney Coleman, Rekha Chaudhuri, Kian Fan Chung, Jadwiga Wedzicha, Sejla Saglani, Marc P Van der Schee, Liam Heaney, Arnaud BourdinGraham Roberts, Ratko Djukanovic, Piotr Kuna, Maceij Kupczyk, Judith Axmann, Heribert Staudinger, Graham W Clarke, Sven Erik Dahlen, Chris Brightling

Research output: Contribution to journalArticlepeer-review

Abstract

The 3TR (Taxonomy, Treatments, Targets and Remission) consortium is the largest IMI (Innovative Medicine Initiative) project ever started in the field of immune diseases (https://3tr-imi.eu/). 3TR is unique in bringing several medical specialties, encompassing respiratory medicine, rheumatology, neurology and gastroenterology, together, to study disease mechanisms across seven disease entities: asthma, COPD, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, ulcerative colitis and Crohn's disease.
Original languageEnglish
JournalEuropean Respiratory Journal
Volume58
Issue number4
Early online date21 Oct 2021
DOIs
Publication statusEarly online date - 21 Oct 2021

Keywords

  • Cross-Sectional Studies
  • Pulmonary Disease, Chronic Obstructive - drug therapy
  • Humans
  • Asthma - drug therapy

Fingerprint

Dive into the research topics of '3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD'. Together they form a unique fingerprint.

Cite this